NEW YORK (GenomeWeb) – Targos will provide its expertise, biomarker services, and quality standards to support WuXi PharmaTech's bioanalytical work for pharmaceutical customers as part of a biomarker collaboration announced today by the companies.
Targos and WuXi will focus on validating and analyzing clinical tissue biomarkers in cancer, they said, adding Targos is providing training and education to help pathologists and histotechnologists produce accurate, objective, and reproducible diagnostic results.
"By adding these new molecular pathology testing services from Targos, WuXi will provide customers with a comprehensive platform of services in soluble, cell, and tissue biomarkers," the firms said.
Financial and other terms of the agreement were not disclosed.
Earlier this week, Targos' Molecular Pathology business announced a partnership with Akesogen to offer traditional pathology and molecular biomarker services to the pharmaceutical and biotechnology industry.